The US Court of Appeals for the Second Circuit ruled on April 29 that a so-called ‘reverse payment patent settlement’ between pharmaceutical company Bayer and three generic drugs companies did not violate US antitrust laws.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
US, Court of Appeals, Bayer, reverse, payment, patents